Muromonab‐CD3 (T cell) vs other antibody (stratified by comparator)
Muromonab‐CD3 (T cell) showed no clear difference in failure of acute rejection reversal compared with other antibody (stratified by comparator) (moderate certainty).
- Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes onlyRR 1.84 [0.92, 3.67]2 studies · 132 participantsModerate